A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this long-term observational study is designed to collect additional
information on incidence of cancer and cause of death among patients who have participated in
clinical trials of infliximab in the treatment of COPD. Patients must have received at least
1 dose of study agent (ie, placebo or infliximab) in the primary studies to be eligible for
participation in this long-term follow-up study. Information on deaths and cancers will be
collected twice yearly for a period of 5 years from each patient's last safety visit in the
primary study.